VivoSeq
Other

Platinum-Resistant

3

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Platinum-resistant is an early-stage landscape with 3 programs across 4 companies. The most active players are Essen Biotech, Eli Lilly, Ascentage Pharma Group Inc..

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Essen Biotech

1 program

Phase 1Eli Lilly logo

Eli Lilly

0 programs

PreclinicalAscentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

0 programs

PreclinicalV

Vascular Biogenics Ltd. operating as VBL Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

3programs
Small molecule133%
Protein / enzyme133%
Cell therapy133%

Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed3 · 30%
Active, not recruiting3 · 30%
Recruiting2 · 20%
Unknown status1 · 10%
Terminated1 · 10%

Clinical Trials

Trial Activity

10 trials

Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
Recruiting·SStanford University·Phase 1·NCT06646627·48 enrolled
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Recruiting·Ascentage Pharma Group Inc. logoAscentage Pharma Group Inc.·Phase 1·NCT06687070·50 enrolled
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT04395079·9 enrolled
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
Active, not recruiting·NNational University Hospital, Singapore·Phase 1/2·NCT03813394·48 enrolled
Phase I Study Evaluating the Feasibility and Safety of Infusion of "Re-Stimulated" Autologous TILs Followed by Low-Dose IL-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Active, not recruiting·UUniversity Health Network, Toronto·Phase 1·NCT01883297·3 enrolled
A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT01283035·6 enrolled
Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer
Completed·SSouthern Europe New Drug Organization·Phase 2·NCT02643056·32 enrolled
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
Completed·VVascular Biogenics Ltd. operating as VBL Therapeutics·Phase 1/2·NCT01711970·38 enrolled
Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
Terminated·Eli Lilly logoEli Lilly·Phase 2·NCT00055432
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer
Unknown status·UUniversity College, London·Phase 2·NCT03430700·28 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)